Revision as of 01:23, 7 May 2023

Section editor transclusions POEMS: Peripheral neuropathy, Organomegaly, Endocrinopathy, Monoclonal plasma cell disorder, and Skin changes

1 regimens on this page 1 variants on this page

Guidelines

2018: Gavriatopoulou et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias PubMed

Rd: Revlimid (Lenalidomide) & low-dose dexamethasone

Study	Evidence
Nozza et al. 2017	Phase 2, <20 pts

28-day cycle for at least 6 cycles

Nozza A, Terenghi F, Gallia F, Adami F, Briani C, Merlini G, Giordano L, Santoro A, Nobile-Orazio E. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol. 2017 Dec;179(5):748-755. Epub 2017 Oct 19. link to original article contains dosing details in manuscript PubMed

@@ Line 3: / Line 3: @@
 [[#top|Back to Top]]
 </div>
-{| class="wikitable" style="text-align:center; width:50%;"
+{{#lst:Section editor transclusions|pcd}}
-!colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Section editor'''
-|-
-|style="background-color:#F0F0F0"|[[File:Headshot Cowan.jpg|frameless|upright=0.3|center]]
-|<big>[[User:Andrewc072|Andrew J. Cowan, MD]]<br>University of Washington<br>Seattle, WA</big><br>[[File:Social-twitter-icon.png|frameless|upright=0.1]] [https://twitter.com/andrewcowanmd andrewcowanmd]<br>[https://www.linkedin.com/in/andrew-cowan-63b3a130/ LinkedIn]
-|-
-|}
 <big>'''POEMS:''' '''<u>P</u>'''eripheral neuropathy, '''<u>O</u>'''rganomegaly, '''<u>E</u>'''ndocrinopathy, '''<u>M</u>'''onoclonal plasma cell disorder, and '''<u>S</u>'''kin changes</big>
 {| class="wikitable" style="float:right; margin-right: 5px;"